Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension for the topical treatment of ear infections: A review of the literature

Pediatric Infectious Disease Journal

Volumn 28, Issue 2, 2009, Pages 141-144

  Wall, G Michael ^a   Stroman, David W ^a   Roland, Peter S ^b   Dohar, Joseph ^c  

^a ALCON RESEARCH LTD   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Acute otitis externa; Acute otitis media; Ciprofloxacin; Dexamethasone

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; CIPROFLOXACIN; CIPROFLOXACIN PLUS DEXAMETHASONE; CORTISPORIN; DEXAMETHASONE; HYDROCORTISONE; OFLOXACIN; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT;

ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; EAR CONGESTION; EAR DISCOMFORT; EAR INFECTION; EAR PRURITUS; EAR RESIDUE; ERYTHEMA; EXTERNAL OTITIS; HUMAN; INFECTION COMPLICATION; IRRITABILITY; OTALGIA; OTITIS MEDIA; OTOTOXICITY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TASTE AVERSION; TREATMENT FAILURE; TYMPANOSTOMY TUBE; DRUG COMBINATION; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; CIPROFLOXACIN; DEXAMETHASONE; DRUG COMBINATIONS; HUMANS; OTITIS EXTERNA; OTITIS MEDIA;

EID: 61949099703     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31818b0c9c     Document Type: Article

References (47)

1. Myer CM. Historical perspective on the use of otic antimicrobial agents. Pediatric Infect Dis J.2001;20:98 -101.
2. Roland PS, Rutka JA. Ototoxicity.Hamilton, Ontario: BC Decker; 2004.
3. Rohn GN, Meyerhoff WL, Wright CG. Ototoxicity of topical agents. Otolaryngol Clin N Am.1993;26:747-758.
4. Morizono T, Paparella MM, Juhn SK. Ototoxicity of propylene glycol in experimental animals. Am J. Otolaryngol.1980;1:393-399.
5. CIPRODEX® Sterile otic suspension. Available at: http://a1020.g. akamai.net/7/1020/2226/66c99f43327aaf/ecatalog.alcon.com/pi/CiprodexOticSusp-us- en.pdi. Accessed April 16, 2007.
6. Cipro® HC Otic NDA -20805 approval. Available at: http://www.fda.gov/cder/foi/nda/98/20805-mr.pdf. Accessed April 17, 2007.
7. FLOXIN® Otic prescribing information. Available at: http://www.floxinotic.com. Accessed April 17, 2007.
8. Bluestone CD, Klein, J.O. Otitis Media in Infants and Children.3rd ed. Philadelphia, PA: WB Saunders Company; 2001:59.
9. Roland PS, Stroman DW. Microbiology of acute otitis externa. Laryngoscope.2002;112:1166-1177.
10. Hannley M, Denneny JC III, Holzer SS. Use of ototopical antibiotics in treating 3 common ear diseases. Otolaryngol Head eck Surg.2000;122: 934-940.
11. Rosenfeld RM, Brown L, Cannon CR, et al. American Academy of Otolaryngology-Head Neck Surgery Foundation. Clinical practice guideline: acute otitis externa. Otolaryngol Head Neck Surg.2006;134(suppl 4):S4-S23.
12. Issacson G, Rosenfeld RM. Care of the child with tympanostomy tubes. Pediatric Clin North Am.1996;43:1183-1193.
13. Hochman J, Blakley B, Abdoh A, et al. Post-tympanostomy tube otorrhea: a meta-analysis. Otolaryngol Head Neck Surg.2006;135:8 -11.
14. Roland PS, Parry DA, Stroman DW. Microbiology ofacute otitis media with tympanostomy tubes. Otolaryngol Head Neck Surg.2005;133:585-595.
15. Spektor Z, Jasek MC, Jasheway D, et al. Pharmacokinetics of CIPRODEX® otic in pediatric and adolescent patients. Int J Pediatr Otorhinolaryngol.2008;72:97-102.
16. Claes J, Govaerts PJ, Van de Heyning Ph, et al. Lack of ciprofloxacin ototoxicity after repeated ototopical application. Antimicrob Agents Chemother.1991;35:1014-1016.
17. Ikiz AO, Serbetcioglu B, Guneri EA, et al. Investigation of topical ciprofloxacin ototoxicity in guinea pigs. Acta Otolaryngol.1998;118:808- 812.
18. Brownlee RE, Hulka GF, Prazma J, et al. Ciprofloxacin use as a topical otic preparation. Arch Otolaryngol Head Neck Surg.1992;118:392-396.
19. Becvaroski Z, Kartush JM, Bojrab DI. Intratympanic ciprofloxacin and the human labyrinthine sampling model. Laryngoscope.2002;112:686-688.
20. Thomas SP, Buckland JR, Rhys-Williams R. Potential ototoxicity from triamcinolone, neomycin, gramicidin and nystatin (Tri-AdcortylTM) cream. J Laryngology Otology.2005;119:48 -50.
21. Halama AR, Wright CG, Meyerhoff WL. Ototoxicity of an ototopical preparation-experimental results and clinical facts. Acta Otorhinolaryngologica Belg.1991;45:279 -282.
22. Bath A, Walsh RM, Bance ML, et al. Ototoxicity of topical gentamicin preparations. Laryngoscope.1999;109(7 Pt 1):1088 -1093.
23. Morizono T. Toxicity of ototopical drugs: animal modeling. Ann Otol Rhinol Laryngol.1990;99:42-45.
24. Spandow O. Are glucocorticoids in ear drops ototoxic? Acta Otolaryngol.1992;Suppl 493:89-91.
25. Kaplan DM, James A, Thorp MA, et al. Effects of middle ear application of Cipro HC otic suspension in an animal model. J Otolaryngology.2004;33: 160-164.
26. Kaufman RS. The use of tissue adhesive (isobutyl cyanoacrylate) and topical steroid (0.1 percent dexamethasone) in experimental tympanolplasty. Laryngoscope.1974;84:793-804.
27. Oshima T, Abe S, Tsutsui Y, et al. Influences of hydrocortisone 17-butyrate 21-propionate on the visual and the auditory organs. J Toxicol Sci.1981; 6(suppl):141-158.
28. Guzman J, Ruiz J, Eshraghi AA, et al. Triamcinolone acetonide protects auditory hair cells from 4-hydroxy-2,3-nonenal (HNE) ototoxicity in vitro. Acta Otolaryngol.2006;126:685-690.
29. Russell PT, Church CA, Jinn TH, et al. Effects of common topical preparations on the morphology of isolated cochlear outer hair cells. Acta Otolaryngol.2001;121:135-139.
30. Shefelbine SE, Young LJ, Antonelli PJ. Mitigation of hearing loss from semi-circular canal transaction in pseudomonas otitis media with ciprofloxa- cin-dexamethasone irrigation. Otol Neurotol.2006;27:265-269.
31. Hebda PA, Yuksel S, Dohar JE. Effects of ciprofloxacin-dexamethasone on myringotomy wound healing. Laryngoscope.2007;117:522-528.
32. Ciprodex (Ciprofloxacin & Dexamethasone) Sterile Otic Solution. Application No: 021537. Medical Review(s). Available at: http://www.fda.gov/ cder/foi/nda/2003/021537-Ciprodex-medr.PDF?bcsi-scan-0FB272F24E6BDA79= 0&bcsi-scan- filename=021537-Ciprodex-medr.PDF. Accessed May 14, 2007.
33. Roland PS, Pien FD, Schultz CC, et al. Efficacy and safety of topical ciprofloxacin/dexamethasone versus neomycin/polymyxin B/hydrocortisone for otitis externa. Curr Med Res Opin.2004;20:1175-1183.
34. Roland PS, Younis R, Wall GM. A comparison of ciprofloxacin/dexameth- asone and neomycin/polymyxin/hydrocortisone for otitis externa pain. Adv Ther.2007;24:671-675.
35. Rahman A, Rizwan S, Waycaster C, et al. Pooled analysis of two clinical trials comparing the clinical outcomes of topical ciprofloxacin/dexamethasone otic suspension and polymyxin B/neomycin/hydrocortisone otic suspension for the treatment of acute otitis externa in adults and children. Clin Ther.2007;29:1950-1956.
36. Roland PS, Anon JB, Moe RD, et al. Topical ciprofloxacin/dexamethasone is superior to ciprofloxacin alone in pediatric patients with acute otitis media and otorrhea through tympanostomy tube. Laryngoscope.2003;113:2116-2122.
37. Roland PS, Kreisler LS, Reese B, et al. Topical ciprofloxacin/ dexamethasone otic suspension is superior to ofloxacin otic solution in the treatment of children with acute otitis media with otorrhea through tympanostomy tube. Pediatrics.2004;113:e40-e46.
38. Dohar J, Giles W, Roland PS, et al. Topical ciprofloxacin/dexamethasone superior to oral amoxicillin/clavulanic acid in acute otitis media with otorrhea through tympanostomy tube. Pediatrics.2006;118:e561-e569.
39. Roland PS, Dohar JE, Lanier BJ, et al. Topical ciprofloxacin/ dexamethasone otic suspension is superior to ofloxacin otic solution in the treatment of granulation tissue children with acute otitis media with otorrhea through tympanostomy tubes. Otolaryngol Head Neck Surg.2004;130:736-741.
40. Wright CG, Meyerhof WL. Pathology of otitis media. Ann Otol Rhinol Laryngol Suppl.1994;163:24-26.
41. Giles W, Dohar J, Iverson K, et al. Ciprofloxacin/dexamethasone drops decrease the incidence of physician and patient outcomes of otorrhea after tube placement. Int JPediatr Otorhinolaryngol.2007;71:747-756.
42. Starkweather A, Friedman RA. Effect of Ciprodex on graft healing in tympanoplasty. Adv Ther.2007;24:427-435.
43. 3. Waycaster C, Cockrum P, Reese B, et al. Treatment of acute otitis media in children with tympanostomy tubes: a caregiver's perspective. Pharm Ther.2004;29:721-722, 729 -730.
44. 4. Roland PS, Pontius A, Wall GM, et al. A cost threshold analysis of ciprofloxacin-dexamethasone versus ofloxacin for acute otitis media in pediatric patients with tympanostomy tubes. Clin Ther.2004;26:1168 -1178.
45. Roland PS, Waycaster CR, Wall GM, et al. An economic evaluation of two ototopical treatments for acute otitis media in tympanostomy tube patients. Value Health.2006;9:219-226.
46. Center for Disease Control and Prevention. Get smart: know when antibiotics work. April 21, 2006. Available at: http://www.cdc.gov/ drugresistance/community/anitbiotic-resistance.htm. Accessed April 12, 2007.
47. Weber PC, Roland PS, Hannley M, et al. The development of antibiotic resistant organisms with the use ofototopical medications. Otolaryngol Head Neck Surg.2004;130(suppl 3):S89-S94.